CPHL financials Citi Pharma Ltd.
Citi Pharma Ltd. (CPHL) has 5 financial years on file, from the year to 30 Jun 2022. The latest, the year to 30 Jun 2026 earned Rs 3.43 a share on sales of Rs 14.0 bn. 5 quarters are listed below the years.
Results by financial year
Company accounts as filed. Earnings per share are on today’s share count where a split or bonus issue came later. Years to 30 June. 5 years and 5 of the last 8 quarters.
Earnings per share by financial year
| Year | Earnings per share (Rs) | Sales | Gross margin | Net profit as a share of sales | Change in earnings per share on the year before |
|---|---|---|---|---|---|
| Year to 30 Jun 2026 | 3.43 | Rs 14.0 bn | 17.5% | 5.6% | -12.1% |
| Year to 30 Jun 2025 | 3.90 | Rs 13.2 bn | 15.3% | 6.8% | +6.8% |
| Year to 30 Jun 2024 | 3.65 | Rs 12.4 bn | 12.8% | 6.7% | +26.7% |
| Year to 30 Jun 2023 | 2.88 | Rs 12.4 bn | 12.2% | 5.3% | 0.0% |
| Year to 30 Jun 2022 | 2.88 | Rs 9.8 bn | 13.8% | 6.5% | — |
Results by quarter
5 of the last 8 quarters. The fourth quarter is filed only inside the annual accounts.
| Quarter | Earnings per share (Rs) | Sales | Profit after tax | Net profit as a share of sales | Change on the same quarter a year before |
|---|---|---|---|---|---|
| Quarter to 30 Sep 2026 | 1.02 | Rs 3.4 bn | Rs 233.2 m | 6.9% | +14.6% |
| Quarter to 31 Mar 2026 | 1.21 | Rs 3.1 bn | Rs 275.4 m | 8.9% | +26.0% |
| Quarter to 31 Dec 2025 | 1.77 | Rs 4.3 bn | Rs 404.3 m | 9.3% | — |
| Quarter to 30 Sep 2025 | 0.89 | Rs 3.4 bn | Rs 203.7 m | 6.0% | — |
| Quarter to 31 Mar 2025 | 0.96 | Rs 3.3 bn | Rs 220.4 m | 6.6% | — |
Annual report figures: income and balance sheet
From each annual report. A blank is a line this page does not show for that year.
| Year | Revenue | Gross profit | Profit after tax | Total assets | Equity | Liabilities | Return on equity | Current ratio | Basis |
|---|---|---|---|---|---|---|---|---|---|
| Year to 30 Jun 2026 | Rs 14.0 bn | Rs 2.4 bn | Rs 782.6 m | Rs 18.1 bn | Rs 10.8 bn | — | 7.2% | — | unknown |
| Year to 30 Jun 2025 | Rs 13.2 bn | Rs 2.0 bn | Rs 892.0 m | Rs 18.4 bn | Rs 10.9 bn | — | 8.2% | — | unknown |
| Year to 30 Jun 2024 | Rs 12.4 bn | Rs 1.6 bn | Rs 833.5 m | Rs 11.4 bn | Rs 5.6 bn | — | 14.8% | — | unknown |
| Year to 30 Jun 2023 | Rs 12.4 bn | Rs 1.5 bn | Rs 658.0 m | Rs 10.0 bn | Rs 5.4 bn | — | 12.3% | — | unknown |
| Year to 30 Jun 2022 | Rs 9.8 bn | Rs 1.4 bn | Rs 653.7 m | Rs 8.1 bn | Rs 4.7 bn | — | 13.9% | — | unknown |
Source: annual report, page 37.
Ratios from the latest annual report
- Return on equity
- 7.2%
- Return on assets
- 4.3%
- Book value a share
- Rs 47.39
- Price to book value
- 1.34 times
- Equity as a share of assets
- 59.7%
- Gross margin
- 17.5%
- Operating margin
- 13.8%
As of 30 Jun 2026.
More on CPHL
- CPHL share price and overview
- CPHL dividend history
- Pharmaceuticals sector
- CWHC financials · Crestwell Healthcare Limited
- FEROZ financials · Ferozsons Laboratories Limited
- GLAXO financials · GlaxoSmithKline Pakistan Limited
- ABOT financials · Abbott Laboratories (Pakistan) Limited
- HALEON financials · Haleon Pakistan Limited
- HINOON financials · Highnoon Laboratories Limited
Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .